PENTIXAPHARM
6.2.2020 12:48:05 CET | Business Wire | Press release
PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers. Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.
Interviews:
“With the renowned expertise of the PentixaPharm team, the company is well positioned to bring the lead-compounds PentixaFor and PentixaTher with an effective clinical development program to the next level. We are thrilled to accompany this venture.”,
says Phillip Eckert, Responsible Programme Manager and Partner at ELSA.
“Scintomics is very excited about this new partnership marking another important milestone towards a strong positioning of PentixaPharm as radiopharmaceutical development specialist” , comments Saskia Kropf, CEO of Scintomics. Prof. Hans-Jürgen Wester, founder of Scintomics, adds: “We are enthusiastic by this round A financing to advance the CXCR4 program. Preclinical and clinical data so far have demonstrated encouraging evidence and good potential for targeted cancer therapies. Now with the experienced development team of PentixaPharm, we are sure to quickly establish this theranostic approach towards meaningful clinical trials.”
“We are delighted that in ELSA we have found a strong financing partner with an outstanding expertise in the radiopharmaceutical field. The proceeds of the series A financing will enable us to bring a new treatment for CNS Lymphoma, up to today a disease with limited treatment options, a little closer to patients in need”, adds Anna Steeger, Co-founder of 1717 LSV GmbH and CEO of PentixaPharm.
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The [68 Ga]Gallium based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukemia, lymphoma, and multiple myeloma – but also for solid tumors like adrenocortical carcinoma and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke can be visualised with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About ELSA Eckert Life Science Accelerator
ELSA, a subsidiary of Eckert Wagniskapital und Frühphasenfinanzierung, is a Berlin-based life science incubator with over two decades of experience in the venture capital industry. ELSA invests primarily in start-up companies, which are in need of first-round venture capital financing and actively supports them during the transformation process from start-ups into mature companies.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalised cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Introduces AQUASCENT™: Advanced Water-Based Fragrance Technology30.9.2026 09:00:00 CEST | Press release
New innovation from IFF’s Science of Performance platform offers greater transparency and olfactive performance for fine fragrance IFF (NYSE: IFF), a global leader in flavors, fragrances and health and biosciences, today introduced AQUASCENT™, a new vegan, water-based carrier for fine fragrance. Crafted from a proprietary formula made with biodegradable materials, AQUASCENT™ delivers enhanced olfactive performance and visual clarity for consumers while supporting a more sustainable approach to shipping the product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929938674/en/ AQUASCENT™ is IFF's new water-based fragrance carrier technology that maintains visual clarity while supporting fragrance loads from 10% to up to 25%, compared with up to 15% for most comparable systems. “AQUASCENT™ reflects our continued investment in new scent technologies and formats that create compelling fragrance experiences while supporting the
PREPAR-VIE Selects Clearwater Analytics to Modernize and Replace Its Investment Management System30.9.2026 09:00:00 CEST | Press release
French life insurer selects Clearwater’s front-to-back platform to support the transition Clearwater Analytics today announced that PREPAR-VIE, a life insurance company managing more than €9 billion in assets, has selected Clearwater as its technology partner to unify its front-to-back investment operations within a single, integrated platform. According to S&P Global Ratings, France is among the key drivers of life insurance growth in Europe, as insurers continue to shift their offerings toward unit-linked products. In this context, the best-positioned players are those with real-time visibility across the entire investment lifecycle. With Clearwater, PREPAR-VIE will simplify its investment operations and streamline reporting for both its general account and its unit-linked investments within a single platform. Clearwater covers the entire investment lifecycle — from portfolio and order management to multi-standard investment accounting (French GAAP and IFRS), reconciliation, and unit
SES and Sky Sign Multi-Year Satellite Capacity Agreement30.9.2026 08:50:00 CEST | Press release
The renewal extends the companies' partnership into next decade, supporting premium television services across the UK and Ireland SES and Sky have extended their long-standing partnership in a new multi-year agreement for direct-to-home (DTH) satellite services across the United Kingdom and Republic of Ireland, running into the next decade. Under the agreement, Sky will continue to leverage SES's satellite capacity at the 28.2 degrees East orbital position to deliver television services to millions of households across the region. The renewal extends a partnership that dates to 1988 and reinforces satellite's ongoing role in delivering premium television experiences at scale. “As we give customers more choice in how they access Sky, satellite continues to play an important role in how we deliver our services to customers across the UK and Ireland,” said Nick Herm, Group Chief Operating Officer, Sky. “This agreement with SES provides the reliability, reach and service quality we need to
rhode Launches at Sephora in Europe, Marking Its First Retail Presence Across 19 New Markets30.9.2026 08:30:00 CEST | Press release
The launch brings rhode into physical retail across Europe, previously only being available for purchase in the region through rhodeskin.com rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), is available starting today, Wednesday, 30 September, 2026, at Sephora online and in over 500 stores across Europe. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This follows the 2025 rollout with Sephora in the U.S., Canada, and the U.K. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929500812/en/ rhode launches into Sephora across Europe Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode is the No. 1 overall skincare
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 07:00:00 CEST | Press release
New three-year ARCADIA long-term extension data demonstrate that Nemluviois well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis1 The findings, to be shared at EADV 2026, show that up to 91% of patients achieved at least 75% improvement in eczema severity, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life at Week 1521 Additional analyses to be presented further establish itch and skin lesions as central drivers of sleep disturbance and overall quality of life impairment in prurigo nodularis and atopic dermatitis2,3 Collectively, these data reinforce our understanding of the long-term efficacy and safety profile of Nemluvio and underscore Galderma's long-standing commitment to improving the outcomes that matter most to patients with atopic dermatiti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom